Rivaroxaban: Clinical Trials

486 trials of Rivaroxaban, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

293 completed, 76 unknown, 58 recruiting, 25 terminated. 115 Phase 3, 106 Phase 4, 57 Phase 2, 51 Phase 1, 38 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 3115Completed 63, Unknown 20, Terminated 13, Recruiting 12, Not yet recruiting 5, Active not recruiting 1, Withdrawn 1
Phase 4106Completed 42, Unknown 26, Recruiting 24, Terminated 4, Withdrawn 4, Active not recruiting 3, Not yet recruiting 3
Phase 257Completed 39, Unknown 9, Terminated 4, Recruiting 3, Active not recruiting 1, Withdrawn 1
Phase 151Completed 45, Unknown 3, Recruiting 2, Terminated 1
Not applicable38Recruiting 12, Completed 11, Unknown 8, Not yet recruiting 2, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1
Early Phase 17Unknown 3, Recruiting 2, Not yet recruiting 1, Terminated 1

Follow Rivaroxaban: new trials by email Literature Review of Rivaroxaban trials Research Report on Rivaroxaban

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC) - Venous Thromboembolism, Children Under 2 Years
Not yet recruitingBayer8502027-09-012026-10-02
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG, Placebo Rivaroxaban - Ischemic Stroke
Phase 4Not yet recruitingBrazilian Clinical Research Institute45002027-01-012026-10-30
To Evaluate The Efficacy And Safety Of Rivaroxaban In Combination With Aspirin Compared With Aspirin Monotherapy In Patients With Stable Coronary Artery Disease (CAD) and High Ischemic Risk
rivaroxaban plus aspirin, Aspirin 75 mg daily - Stable Coronary Artery Disease (CAD), Myocardial Infarction
Not applicableNot yet recruitingRepublican Specialized Scientific and Practical Medical Center of Cardiology2002026-11-052026-11-10
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)
Rivaroxaban, ASA - Ischemic Stroke, Intracranial Atherosclerosis
Phase 3Not yet recruitingPopulation Health Research Institute11722026-09-302026-09-01
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Apixaban, Rivaroxaban, Enoxaparin (LMWH) - Total Knee Arthroplasty, Venous Thromboembolism
Not applicableRecruitingMilitary Hospital of Tunis1382026-09-152026-10-16
Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran, Aspirin - Stroke, Acute Ischemic Stroke
Phase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine6802026-08-152026-08-05
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
REGN7508, REGN9933, Placebo - Peripheral Artery Disease (PAD)
Phase 3RecruitingRegeneron Pharmaceuticals70502026-07-102026-11-05
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices - Pulmonary Embolism, Venous Thromboembolism
Not yet recruitingNanjing First Hospital, Nanjing Medical University13002026-06-012026-05-22
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
Apixaban, Rivaroxaban - Atrial Fibrillation
Phase 4RecruitingVA Office of Research and Development100002026-06-012026-09-23
Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening Ischemia
Aspirin tablet, Low-Dose Rivaroxaban Plus Aspirin, - Limb Ischemia
Early Phase 1RecruitingKing Edward Medical University782026-06-012026-09-22
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
Rivaroxaban - Portal Vein Thrombosis, Anticoagulant Therapy
Not applicableNot yet recruitingShanghai Zhongshan Hospital1752026-06-012026-05-22
Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia
Aspirin 100 mg, Clopidogrel 75 mg, Rivaroxaban 15 mg - Coronary Artery Ectasia, Acute Coronary Syndromes (ACS)
Phase 4RecruitingInstituto Nacional de Cardiologia Ignacio Chavez3262026-02-112026-04-09
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
Andexanet alfa, Rivaroxaban, Apixaban - Healthy Participants
Phase 1CompletedAstraZeneca1912026-01-192026-07-09
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Dabigatran, Apixaban, edoxaban - Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Phase 4RecruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre3002026-01-152026-09-24
A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban
Edoxaban, Rivaroxaban - Atrial Fibrillation, Renal Dysfunction
CompletedDaiichi Sankyo82652025-12-252026-10-15
Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention
rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention
Phase 3Not yet recruitingMcMaster University1002025-12-012025-11-14
Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes
Rivaroxaban, Enoxaparin 40 mg - Postpartum Period, Cesarean Section Surgery
Not applicableRecruitingWolfson Medical Center622025-12-012026-09-15
Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
rivaroxaban (10mg), Enoxaparin 40 mg SC - Deep Venous Thromboses, Laparotomy Patients
Phase 4RecruitingMayo Hospital Lahore2122025-10-102025-11-21
Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction
Rivaroxaban, Atorvastatin - Myocardial Injury After Noncardiac Surgery
Early Phase 1RecruitingNYU Langone Health502025-10-072026-04-06
Rivaroxaban for Slow Coronary Flow After PCI in STEMI
Dual Antiplatelet (DAPT) Therapy, Rivaroxaban - ST Elevation Myocardial Infarction, No-Reflow Phenomenon
Phase 4Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine602025-10-012025-09-29

Showing 20 of 486. Sign in to see all of them.

Conditions studied

Atrial Fibrillation (114)  ·  Venous Thromboembolism (89)  ·  Stroke (59)  ·  Venous Thrombosis (54)  ·  Thrombosis (45)  ·  Pulmonary Embolism (36)  ·  Hemorrhage (26)  ·  Thromboembolism (22)  ·  Ischemic Stroke (21)  ·  Coronary Artery Disease (20)  ·  Acute Coronary Syndrome (18)  ·  Neoplasms (18)  ·  Peripheral Arterial Disease (17)  ·  Cardiovascular Diseases (15)  ·  Embolism (15)

Sponsors

Bayer (113)  ·  Janssen Research & Development, LLC (10)  ·  Assistance Publique - Hôpitaux de Paris (8)  ·  Brigham and Women's Hospital (8)  ·  Ottawa Hospital Research Institute (8)  ·  Population Health Research Institute (8)  ·  Insel Gruppe AG, University Hospital Bern (7)  ·  Pfizer (7)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (7)  ·  Bristol-Myers Squibb (5)  ·  Janssen Scientific Affairs, LLC (5)  ·  Centre Hospitalier Universitaire de Saint Etienne (4)  ·  Ottawa Heart Institute Research Corporation (4)  ·  Asan Medical Center (3)  ·  Assiut University (3)

Countries

United States (99)  ·  Canada (82)  ·  Germany (71)  ·  France (67)  ·  China (64)  ·  United Kingdom (58)  ·  Italy (47)  ·  Netherlands (47)  ·  Spain (46)  ·  Belgium (43)  ·  South Korea (43)  ·  Brazil (40)  ·  Sweden (39)  ·  Denmark (37)  ·  Austria (33)

Top investigators

Shirley Wang, PhD, ScM (7)  ·  Jun-Wen Wang, MD (3)  ·  Lana Castellucci, MD, FRCPC (3)  ·  Chao Gao, M.D., Ph.D. (2)  ·  Fang Liu, MD (2)  ·  Gunnar H Gislason, MD, PhD (2)  ·  Ling Tao, M.D., Ph.D. (2)  ·  Madeleine Durand, MD, MSc, FRCPC (2)

Results publications

PMID 37591523, PMID 40163217, PMID 31535314, PMID 34172290, PMID 22371186, PMID 25698905, PMID 29132879, PMID 29132880, PMID 29976287, PMID 31420317, PMID 35244208, PMID 38941511, PMID 21128814, PMID 21570509, PMID 21830957, PMID 22077192, PMID 22664783, PMID 23013426, PMID 23829521, PMID 24053656, PMID 24341332, PMID 24432872, PMID 25717286, PMID 25750589, PMID 25851062, PMID 27030066, PMID 27535349, PMID 28844192, PMID 30121419, PMID 31699660, PMID 31975354, PMID 32657973, PMID 33766266, PMID 34022170, PMID 34755519, PMID 35389229, PMID 36700520, PMID 38189593, PMID 38844941, PMID 40875095, PMID 42389777, PMID 10591382, PMID 1100130, PMID 11546885, PMID 12917889, PMID 15189396, PMID 15234649, PMID 15811953, PMID 15842354, PMID 18094721

NIH funding

2014 (8), 2015 (7), 2016 (4), 2019 (4), 2023 (4), 2017 (3), 2025 (3), 2008 (2), 2009 (2), 2004 (1), 2005 (1), 2018 (1), K23HL151871 (1), R34HL113404 (1), R34HL173301 (1)